2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1117 Comparison of iptacopan and eculizumab in the treatment of complement inhibitor Naïve Paroxysmal nocturnal hemoglobinuria

Leyu Wang, Qi Wang2, Liu Fengling3, Zhuxin Zhang4, Ziwei Liu, MD5, Chen Yang6, Miao Chen, MD7, Junling Zhuang, MD, PhD8, Bing Han9
1 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
3 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
4 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
5 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
6 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
7 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
8 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
9 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Objective To compare the efficacy and safety of iptacopan and eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were complement inhibitor (CI) naive.

Methods This retrospective study collected data from patients with PNH who received treatment with iptacopan or eculizumab at Peking Union Medical College Hospital between February 2023 and December 2025. Clinical data and changes in clinical manifestations and laboratory indicators were collected at 1, 3, and 6 months and during subsequent follow-up. Results A total of 120 patients were included (63 iptacopan, 57 eculizumab), with median follow-up durations of 15 (range, 6–24) and 24 (6–39) months, respectively. Hemoglobin normalization rates were significantly higher in the iptacopan group than in the eculizumab group (82.5% vs. 15.8% at 6 months, 87.2% vs. 25.5% at 12 months, and 84.6% vs. 34.5% at 24 months; all P < 0.01). Transfusion independence was achieved in 100% and 90% of patients, respectively. Lactate dehydrogenase normalization favored iptacopan (75.8% vs. 52.6%, P = 0.008) at 1 month, whereas converged or reversed at later time points (66.7% vs. 63.8% at 12 months; 53.8% vs. 62.1% at 24 months (P>0.05). Breakthrough hemolysis occurred less frequently with iptacopan (11.5 vs. 29.1 per 100 patient-years, P = 0.023). Adverse event rates were comparable (45.9 vs. 41.7 per 100 patient-years, P = 0.735) between the two groups. Clinically significant extravascular hemolysis was observed only in the eculizumab group (35.1%, 22.6%, and 13.6% at 6, 12, and 24 months). Infection-related serious adverse events were observed one in the iptacopan group and two in the eculizumab. No new thrombotic events or breakthrough meningococcal/pneumococcal infections occurred in either group.

Conclusions In this real-world cohort, iptacopan was associated with more favorable hemoglobin responses and comprehensive hemolysis control compared with eculizumab in CI naïve PNH patients.
Leyu Wang: No relevant conflicts of interest to declare.